NZ520500A - Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor - Google Patents

Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor

Info

Publication number
NZ520500A
NZ520500A NZ520500A NZ52050001A NZ520500A NZ 520500 A NZ520500 A NZ 520500A NZ 520500 A NZ520500 A NZ 520500A NZ 52050001 A NZ52050001 A NZ 52050001A NZ 520500 A NZ520500 A NZ 520500A
Authority
NZ
New Zealand
Prior art keywords
alpha
adrenoceptor
disease
pharmacol
angina pectoris
Prior art date
Application number
NZ520500A
Other languages
English (en)
Inventor
Siegfried Wurster
Mia Engstrom
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva-Liisa Savola
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of NZ520500A publication Critical patent/NZ520500A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NZ520500A 2000-02-11 2001-02-07 Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor NZ520500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
NZ520500A true NZ520500A (en) 2005-01-28

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ520500A NZ520500A (en) 2000-02-11 2001-02-07 Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor

Country Status (22)

Country Link
EP (1) EP1253926A1 (es)
JP (1) JP2003522148A (es)
KR (1) KR20020080413A (es)
AU (1) AU780802B2 (es)
BR (1) BR0108221A (es)
CA (1) CA2399421A1 (es)
CZ (1) CZ20022884A3 (es)
EA (1) EA200200846A1 (es)
EE (1) EE200200435A (es)
GE (1) GEP20043356B (es)
HR (1) HRP20020746A2 (es)
HU (1) HUP0300032A3 (es)
IL (1) IL151017A0 (es)
IS (1) IS6476A (es)
MX (1) MXPA02007454A (es)
MY (1) MY133957A (es)
NO (1) NO20023773D0 (es)
NZ (1) NZ520500A (es)
PL (1) PL357872A1 (es)
SK (1) SK11472002A3 (es)
WO (1) WO2001058454A1 (es)
YU (1) YU59102A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
NZ530366A (en) * 2001-07-20 2005-02-25 Juvantia Pharma Ltd Oy Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
CA2399421A1 (en) 2001-08-16
SK11472002A3 (sk) 2003-02-04
HRP20020746A2 (en) 2004-12-31
GEP20043356B (en) 2004-04-13
HUP0300032A2 (en) 2003-05-28
EP1253926A1 (en) 2002-11-06
HUP0300032A3 (en) 2006-01-30
IL151017A0 (en) 2003-02-12
JP2003522148A (ja) 2003-07-22
EA200200846A1 (ru) 2002-12-26
AU3551001A (en) 2001-08-20
YU59102A (sh) 2005-11-28
IS6476A (is) 2002-07-19
EE200200435A (et) 2003-12-15
NO20023773L (no) 2002-08-09
AU780802B2 (en) 2005-04-21
MY133957A (en) 2007-11-30
BR0108221A (pt) 2003-03-05
KR20020080413A (ko) 2002-10-23
WO2001058454A1 (en) 2001-08-16
MXPA02007454A (es) 2004-08-23
PL357872A1 (en) 2004-07-26
CZ20022884A3 (cs) 2003-02-12
NO20023773D0 (no) 2002-08-09

Similar Documents

Publication Publication Date Title
Shahid et al. Tumor necrosis factor-α induces renal vasoconstriction as well as natriuresis in mice
US20030162782A1 (en) Treatment of neuropathy
BG63487B1 (bg) Използване на хетероциклени съединения
KR20070099527A (ko) 유기 화합물의 조합물
Mizobe et al. α2-Adrenoceptor agonists and anesthesia
JP2002526408A (ja) 疼痛および不安の処置のためのmglur5アンタゴニスト
Salomonsson et al. α1-Adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies
JP2021529728A (ja) 慢性腎疾患を持つ糖尿病対象を治療する方法
WO2017221142A1 (en) Wnt inhibitors for use in the treatment of fibrosis
Contreras et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension
JP4380800B2 (ja) マラリアの処置のための(+)メフロキンの使用
TW445147B (en) Pharmaceutical composition for preventing and treating postischemic renal failure and for protecting the ischemic kidney, comprising an AT1-receptor antagonist
Nishikibe et al. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist
WO2022095461A1 (zh) 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途
US6521632B2 (en) Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
NZ520500A (en) Sulfonamides useful for the treatment or prevention of a disease i.e. vascular and coronary heart disease mediated by the alpha-2B-adrenoceptor
KR20030016222A (ko) 수술후 스트레스 예방ㆍ치료제
FI116940B (fi) Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
Miyazawa et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
Pasanisi et al. Effect of calcium channel blockers on adrenergic and nonadrenergic vascular responses in man
JP7317039B2 (ja) 線維症を処置するための化合物および組成物
NZ530366A (en) Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor
US20160159778A1 (en) Novel ureido derivatives of naphthalenesulfonic acids
Goldman et al. Recent inventions on receptor tyrosine kinase RET modulation
NAGATOMO et al. Effect of 3-[2-[4-(o-Methoxyphenyl)-1-piperazinyl] ethyl]-2, 4 (1H, 3H)-quinazolinedione Monohydrochloride (SGB-1534), an Anthihypertensive Agent, on 3H-Prazosin and 3H-p-Aminoclonidine Binding to α1-and α2-Adrenoceptors in Dog Brain and Arta

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)